We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
+1.9%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$3.17M
AUM Growth
+$561K
Cap. Flow
+$147M
Cap. Flow %
4,647.33%
Top 10 Hldgs %
63.1%
Holding
323
New
68
Increased
74
Reduced
74
Closed
84

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$37.9M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$24.5M
3
MRK icon
Merck
MRK
+$12.3M
4
GILD icon
Gilead Sciences
GILD
+$11.7M
5
ACHN
Achillion Pharmaceuticals
ACHN
+$11.6M

Top Sells

Rank Stock Value
1
LRMR icon
Larimar Therapeutics
LRMR
+$4.64M
2
OCUL icon
Ocular Therapeutix
OCUL
+$3.33M
3
ACGN
Aceragen Inc
ACGN
+$2.48M
4
ASPX
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
+$2.06M
5
PRQR icon
ProQR Therapeutics
PRQR
+$1.95M

Sector Composition

Rank Sector Weight
1 Healthcare 9.16%
2 Energy 0.42%
3 Industrials 0.14%
4 Consumer Staples 0.11%
5 Technology 0.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EXEL icon
251
PUT
Exelixis
EXEL
$14B
– –
-2,864
Closed -$438
EYPT icon
252
CALL
EyePoint Inc
EYPT
$996M
– –
-35
Closed -$155
EYPT icon
253
EyePoint Inc
EYPT
$996M
– –
-8,908
Closed -$394
EYPT icon
254
PUT
EyePoint Inc
EYPT
$996M
– –
-89
Closed -$393
GERN icon
255
CALL
Geron
GERN
$911M
– –
-4,859
Closed -$2.45K
GERN icon
256
PUT
Geron
GERN
$911M
– –
-107
Closed -$65
INCY icon
257
CALL
Incyte
INCY
$25.7B
– –
-431
Closed -$2.11K
INSM icon
258
Insmed
INSM
$22.7B
– –
-10,000
Closed -$142K
IRWD icon
259
CALL
Ironwood Pharmaceuticals
IRWD
$616M
– –
-170
Closed -$464
LSTA icon
260
CALL
Lisata Therapeutics
LSTA
$9.65M
– –
-2
Closed -$192
LSTA icon
261
Lisata Therapeutics
LSTA
$9.65M
– –
-76
Closed -$63
LSTA icon
262
PUT
Lisata Therapeutics
LSTA
$9.65M
– –
-2
Closed -$145
PBYI icon
263
CALL
Puma Biotechnology
PBYI
$404M
– –
-358
Closed -$8.54K
PGEN icon
264
Precigen
PGEN
$1.98B
– –
-26,507
Closed -$581K
PLUR icon
265
Pluri
PLUR
$18.1M
– –
-1,488
Closed -$323K
QURE icon
266
uniQure
QURE
$2.72B
– –
-67,313
Closed -$620
SRPT icon
267
PUT
Sarepta Therapeutics
SRPT
$1.62B
– –
-423
Closed -$893
TNXP icon
268
CALL
Tonix Pharmaceuticals
TNXP
$159M
– –
0
– -$171
TNXP icon
269
Tonix Pharmaceuticals
TNXP
$159M
– –
0
– -$345
TNXP icon
270
PUT
Tonix Pharmaceuticals
TNXP
$159M
– –
0
– -$708
TSLA icon
271
Tesla
TSLA
$1.2T
– –
-489,945
Closed -$7.93K
TSLA icon
272
PUT
Tesla
TSLA
$1.2T
– –
-17,415
Closed -$28.2K
TVTX icon
273
CALL
Travere Therapeutics
TVTX
$5.17B
– –
-1,710
Closed -$1.54K
VCEL icon
274
Vericel Corp
VCEL
$2.37B
– –
-876,173
Closed -$2.5K
VNDA icon
275
Vanda Pharmaceuticals
VNDA
$307M
– –
-81,600
Closed -$966K
9 10
11
12 13

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q4 2014 Portfolio in Review

As of Q4 2014, Sabby Management held 323 positions worth $3.17M, up 22% from $2.6M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Sabby Management deployed $147M of net new capital in Q4 2014, opening 68 new positions and adding to 74 existing holdings. Its largest new stake was Pfizer: 1,322,658 shares worth $39.1K.

By sector, the portfolio is most concentrated in Healthcare at 9.2% of assets, up from 6.3% a quarter earlier, followed by Energy and Industrials.

On the sell side, the largest reduction was Larimar Therapeutics, an estimated $4.64M trimmed.

  • Sabby Management's largest Q4 2014 buy was Pfizer: 1,322,658 shares worth $39.1K.
  • Sabby Management added most to Achillion Pharmaceuticals in Q4 2014, an estimated $11.6M increase.
  • Sabby Management's biggest Q4 2014 reduction was Larimar Therapeutics, cutting an estimated $4.64M.
  • Sabby Management fully exited Aceragen Inc in Q4 2014, selling an estimated $2.48M.
  • Sabby Management's ten largest holdings make up 63% of its $3.17M portfolio in Q4 2014.
  • Sabby Management opened 68 new positions and closed 84 in Q4 2014.
  • Sabby Management's portfolio value rose 22% quarter-over-quarter to $3.17M.

Based on Sabby Management's 13F filing for Q4 2014, filed 17 Feb 2015.